- Home
- SBLK vs GERN Comparison
SBLK vs GERN Comparison
Compare SBLK & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBLK
- GERN
- Stock Information
- Founded
- SBLK 2006
- GERN 1990
- Country
- SBLK Greece
- GERN United States
- Employees
- SBLK N/A
- GERN N/A
- Industry
- SBLK Marine Transportation
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- SBLK Consumer Discretionary
- GERN Health Care
- Exchange
- SBLK Nasdaq
- GERN Nasdaq
- Market Cap
- SBLK 2.2B
- GERN 2.5B
- IPO Year
- SBLK N/A
- GERN 1996
- Fundamental
- Price
- SBLK $18.71
- GERN $4.02
- Analyst Decision
- SBLK Strong Buy
- GERN Strong Buy
- Analyst Count
- SBLK 3
- GERN 10
- Target Price
- SBLK $25.00
- GERN $6.95
- AVG Volume (30 Days)
- SBLK 1.6M
- GERN 10.0M
- Earning Date
- SBLK 11-19-2024
- GERN 11-07-2024
- Dividend Yield
- SBLK 14.96%
- GERN N/A
- EPS Growth
- SBLK 10.39
- GERN N/A
- EPS
- SBLK 2.98
- GERN N/A
- Revenue
- SBLK $1,220,003,000.00
- GERN $29,480,000.00
- Revenue This Year
- SBLK $29.89
- GERN $30,930.80
- Revenue Next Year
- SBLK $9.08
- GERN $315.72
- P/E Ratio
- SBLK $6.36
- GERN N/A
- Revenue Growth
- SBLK 24.41
- GERN 9199.68
- 52 Week Low
- SBLK $18.52
- GERN $1.64
- 52 Week High
- SBLK $27.47
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- SBLK 34.30
- GERN 48.45
- Support Level
- SBLK $19.72
- GERN $3.60
- Resistance Level
- SBLK $20.20
- GERN $3.86
- Average True Range (ATR)
- SBLK 0.43
- GERN 0.22
- MACD
- SBLK -0.01
- GERN -0.00
- Stochastic Oscillator
- SBLK 9.41
- GERN 46.67
About SBLK Star Bulk Carriers Corp.
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.